Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is well-situated to benefit from the growing trend of precision medicine in the healthcare industry, with its diverse portfolio of radiopharmaceutical products that can aid in the diagnosis and treatment of various diseases. The company's focus on partnerships and collaborations also allows for potential growth opportunities and further expansion of its product pipeline. With a successful track record and strong financials, Lantheus could see increased demand for its products and potential for future growth in the coming years.

Bears say

Lantheus Holdings is facing a dynamic and competitive environment, leading to potential share losses and a conservative guidance for FY26, as seen in the reiterated revenue and EPS outlook. While the CEO search is in its final stages, the company's current performance and stable financials provide some comfort, but the potential for volatility and uncertainty surrounding the transition remains. Additionally, the company is highly dependent on the success and growth of its key products, making it vulnerable to potential setbacks or underperformance in the future.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.